Blurbs

Analysts’ Top Healthcare Picks: InflaRx (IFRX), Entera Bio (ENTX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on InflaRx (IFRXResearch Report), Entera Bio (ENTXResearch Report) and Rani Therapeutics Holdings (RANIResearch Report) with bullish sentiments.

InflaRx (IFRX)

H.C. Wainwright analyst Edward White maintained a Buy rating on InflaRx today and set a price target of $8.00. The company’s shares closed last Thursday at $2.56.

According to TipRanks.com, White ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -24.8% and a 22.2% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics.

InflaRx has an analyst consensus of Strong Buy.

See today’s best-performing stocks on TipRanks >>

Entera Bio (ENTX)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Entera Bio today and set a price target of $10.00. The company’s shares closed last Thursday at $1.03, close to its 52-week low of $1.02.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -36.1% and a 13.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding AG, MoonLake Immunotherapeutics, and Fresh Tracks Therapeutics.

Currently, the analyst consensus on Entera Bio is a Strong Buy with an average price target of $7.00.

Rani Therapeutics Holdings (RANI)

In a report released today, Andreas Argyrides from Wedbush reiterated a Buy rating on Rani Therapeutics Holdings, with a price target of $19.00. The company’s shares closed last Thursday at $9.32, close to its 52-week low of $8.00.

According to TipRanks.com, Argyrides is ranked 0 out of 5 stars with an average return of -16.1% and a 23.7% success rate. Argyrides covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, BioMarin Pharmaceutical, and Liquidia Technologies.

Currently, the analyst consensus on Rani Therapeutics Holdings is a Moderate Buy with an average price target of $20.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on IFRX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos